Compare ABP & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABP | PDSB |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 49.5M |
| IPO Year | N/A | N/A |
| Metric | ABP | PDSB |
|---|---|---|
| Price | $4.77 | $0.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 18.1K | ★ 592.3K |
| Earning Date | 02-10-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $4.51 | $0.70 |
| 52 Week High | $153.90 | $2.20 |
| Indicator | ABP | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 49.68 |
| Support Level | $4.55 | $0.86 |
| Resistance Level | $5.08 | $0.93 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | -0.23 | -0.00 |
| Stochastic Oscillator | 4.81 | 11.26 |
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.